Author: Patterson, Jean L.; Carrion, Ricardo
Title: Demand for Nonhuman Primate Resources in the Age of Biodefense Cord-id: 6c1rnou3 Document date: 2005_1_1
ID: 6c1rnou3
Snippet: The demand for nonhuman primates will undoubtedly increase to meet biomedical needs in this current age of biodefense. The availability of funding has increased the research on select agents and has created a requirement to validate results in relevant primate models. This review provides a description of current and potential biological threats that are likely to require nonhuman primates for the development of vaccines and therapeutics. Primates have been an invaluable resource in the dissecti
Document: The demand for nonhuman primates will undoubtedly increase to meet biomedical needs in this current age of biodefense. The availability of funding has increased the research on select agents and has created a requirement to validate results in relevant primate models. This review provides a description of current and potential biological threats that are likely to require nonhuman primates for the development of vaccines and therapeutics. Primates have been an invaluable resource in the dissection of viral disease pathogenesis as well as in testing vaccine efficacy. DNA vaccine approaches have been studied successfully for Ebola, Lassa, and anthrax in nonhuman primate models. Nonhuman primate research with monkeypox has provided insight into the role of cytokines in limiting disease severity. Biodefense research that has focused on select agents of bacterial origin has also benefited from nonhuman primate studies. Rhesus macaques have traditionally been the model of choice for anthrax research and have yielded successful findings in vaccine development. In plague research, African green monkeys have contributed to vaccine development. However, the disadvantages of current vaccines will undoubtedly require the generation of new vaccines, thus increasing the need for nonhuman primate research. Unfortunately, the current biosafety level (BSL)-3 and BSL-4 facilities equipped to perform this research are limited, which may ultimately impede progress in this era of biodefense.
Search related documents:
Co phrase search for related documents- abdominal pain and acute infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- abdominal pain and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- abdominal pain and liver enzyme: 1, 2, 3, 4, 5, 6, 7, 8
- abdominal pain and lymphocyte decrease: 1, 2, 3
- actual risk and acute respiratory syndrome: 1, 2, 3, 4, 5
- acute infection and live vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute infection and liver enzyme: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute infection and lymph gland: 1, 2
- acute infection and lymphocyte decrease: 1, 2, 3, 4
- acute infection cause and live vaccine: 1
- acute infection cause and lymphocyte decrease: 1
- acute respiratory syndrome and live vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and liver enzyme: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and liver viremia: 1
- acute respiratory syndrome and lymph gland: 1, 2
- acute respiratory syndrome and lymphocyte decrease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- liver viremia and lymph gland: 1
Co phrase search for related documents, hyperlinks ordered by date